Plain-English translation of NCT06792604 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Anal Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether changes in your DNA (specifically something called 'genome methylation') can be used as a screening tool to detect anal cancer early. Researchers will collect samples from people at higher risk of anal cancer and follow them over three years to see if this DNA marker is useful for catching cancer before symptoms develop.
Anal cancer is rare but serious, and it affects certain groups—like men with HIV, transplant recipients, and women with previous HPV-related cancers—at much higher rates. Currently, screening relies on older methods, and doctors need better, simpler ways to identify people who may be developing anal cancer early when treatment is most effective.
You likely qualify if…
You likely don't qualify if…
You will have an initial visit where doctors will examine you and collect a sample (a smear or self-collected sample). If you test positive for a virus called HPV16, you'll be monitored more closely with visits at 1, 2, and 3 years; if negative, you'll have one follow-up visit at 3 years. At each visit, you'll provide samples and answer a brief questionnaire. If symptoms appear or certain test results are abnormal, your doctor may recommend additional imaging or a biopsy as part of your standard care.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
France